Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00084240
Status:
TERMINATED
Last Update Posted:
2008-11-02
First Post:
2004-06-09
Brief Title:
Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated Symptomatic Falciparum Malaria In Southeast Asia
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase 23 Randomized Comparative Double Blind Trial Of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated Symptomatic Falciparum Malaria In Southeast Asia
Status:
TERMINATED
Status Verified Date:
2008-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
See Detailed Description
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective is to confirm the hypothesis that azithromycin optimal dose once daily for three days plus chloroquine is non-inferior to sulfadoxine-pyrimethamine plus chloroquine for the treatment of uncomplicated symptomatic malaria due to P falciparum
Detailed Description:
The trial was terminated prematurely 2 June 2005 due to the inability to recruit the planned number of subjects There were no safety or efficacy concerns regarding the study in the decision to terminate the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None